Small-molecule inhibitors targeting LSD1 have demonstrated promising antitumor activity in preclinical models of malignancies such as acute myeloid leukemia (AML), SCLC, and medulloblastoma [10,11,12,13]. Here, KDM1A is linked to acute myeloid leukemia.